Ryman Davis C, Acosta-Baena Natalia, Aisen Paul S, Bird Thomas, Danek Adrian, Fox Nick C, Goate Alison, Frommelt Peter, Ghetti Bernardino, Langbaum Jessica B S, Lopera Francisco, Martins Ralph, Masters Colin L, Mayeux Richard P, McDade Eric, Moreno Sonia, Reiman Eric M, Ringman John M, Salloway Steve, Schofield Peter R, Sperling Reisa, Tariot Pierre N, Xiong Chengjie, Morris John C, Bateman Randall J
From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universität Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medellín, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.
Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13.
To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD.
We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study.
We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10(-16), r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex.
Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.
确定影响常染色体显性阿尔茨海默病(ADAD)症状出现年龄和病程的因素,并制定基于证据的ADAD症状出现预测标准。
我们收集了来自387个ADAD家系的症状出现年龄和死亡的个体水平数据,这些数据汇编自137篇同行评审出版物、显性遗传阿尔茨海默病网络(DIAN)数据库以及两个具有哥伦比亚(PSEN1 E280A)和伏尔加德意志(PSEN2 N141I)血统的大家系。我们的综合数据集包括3275名个体,其中1307名受ADAD影响且症状出现年龄已知。我们评估了几个因素对发病年龄的相对影响,包括父母的发病年龄、按突变类型和家系划分的发病年龄,以及APOE基因型和性别。我们还使用了在DIAN研究中纵向跟踪的183名ADAD突变携带者的症状出现数据进行生存分析。
我们报告了174个ADAD突变的发病年龄和病程的汇总统计数据,并发现个体症状出现年龄与基于父母发病年龄以及按突变类型和家系划分的平均发病年龄的预测值之间存在强且高度显著(p < 10⁻¹⁶,r² > 0.38)的相关性,在控制APOE基因型和性别后这种相关性仍然存在。
ADAD中观察到的症状出现年龄差异的很大一部分可以由家族史和突变类型来解释,这为在临床研究中使用这些数据估计发病情况提供了实证支持。